AI, Wearable Devices, and Artificial Wombs: ACC Session Highlights Advancements in Cardiac Technology

Experts outlined updates in the use of artificial intelligence, wearable devices, and artificial wombs for cardiac health during a session at the American College of Cardiology (ACC)’s 71st Scientific Sessions. In a session deemed “straight out of science fiction” and “akin to a Star Trek episode” by audience members, panelists at the American College of Cardiology (ACC)’s 71st Scientific Session highlighted recent advancements in direct-to-consumer heart monitor devices, the use of artificial intelligence (AI) in cardiology, and the potential of an artificial womb for babies with congenital heart disease.

The session, titled “Innovations in Treatment of Congenital Heart Disease,” was followed by an audience question and answer session, where concerns regarding Health Insurance Portability and Accountability Act (HIPAA) compliance were raised, along with inquiries about clinician reimbursement for management of direct-to-consumer heart data. In her session, Jennifer Silva, MD, director of pediatric electrophysiology at Washington University in St Louis, Missouri, outlined one ideal integration of remote patient monitoring data collected via wearable devices (eg, Apple Watch, Owlet, AliveCor) into cardiology management.

Self-described as an “avid fan of digital health, AI, and remote patient monitoring technologies, both as user and a developer,” Silva took time to define the goals of remote patient monitoring in health care, emphasizing that the tools should provide early or real-time detection of disease and, ideally, reduce hospitalizations among users. The devices can also be used to improve care efficiency when used correctly and monitor treatment efficacy in real-world settings.